
Instead of investing in technologies to test a few genes at a time, researchers and regulators should plan for the routine use whole-genome sequencing in the diagnosis of cancer, according to speakers at the "Transforming Cancer Care through Diagnostics and Personalized Medicine" symposium, held in Washington, DC, in October.

